These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 11998091)
1. Treatments for overactive bladder. Newton M; Kosier JH; Smith D Urol Nurs; 2000 Aug; 20(4):267-8. PubMed ID: 11998091 [No Abstract] [Full Text] [Related]
2. Anticholinergic drugs for overactive bladder. Kripke C Am Fam Physician; 2006 Jan; 73(1):66. PubMed ID: 16417066 [No Abstract] [Full Text] [Related]
3. New treatment options for overactive bladder and incontinence. Newman DK Director; 2002; 10(3):74-6. PubMed ID: 12116753 [No Abstract] [Full Text] [Related]
4. Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder? Hartnett NM; Saver BG J Fam Pract; 2001 Jul; 50(7):571. PubMed ID: 11485700 [No Abstract] [Full Text] [Related]
5. RE: Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. Ellsworth P J Urol; 2003 Sep; 170(3):928; author reply 928. PubMed ID: 12913741 [No Abstract] [Full Text] [Related]
6. Achieving bladder control. Treatment in the primary care setting. Maloney CM; Cafiero M Adv Nurse Pract; 2002 May; 10(5):73-8. PubMed ID: 12420535 [No Abstract] [Full Text] [Related]
7. Contemporary treatment options for overactive bladder. Taylor PH; Sussman DO JAAPA; 2005 Nov; Suppl():3-13; quiz 14-5. PubMed ID: 16315503 [No Abstract] [Full Text] [Related]
8. Detrol LA and Diropan XL for overactive bladder. Med Lett Drugs Ther; 2001 Apr; 43(1101):28. PubMed ID: 11283473 [No Abstract] [Full Text] [Related]
9. Medication update. Slagle M South Med J; 2002 Feb; 95(2):188-91. PubMed ID: 11846243 [No Abstract] [Full Text] [Related]
10. Medical treatment of overactive bladder. Rackley R; Wein A; Nelson D Mayo Clin Proc; 2001 Nov; 76(11):1179-80. PubMed ID: 11702910 [No Abstract] [Full Text] [Related]
11. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055 [TBL] [Abstract][Full Text] [Related]
12. Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial. Appell RA Curr Urol Rep; 2002 Oct; 3(5):343-4. PubMed ID: 12354340 [No Abstract] [Full Text] [Related]